Copyright
©2007 Baishideng Publishing Group Co.
World J Gastroenterol. Feb 14, 2007; 13(6): 950-954
Published online Feb 14, 2007. doi: 10.3748/wjg.v13.i6.950
Published online Feb 14, 2007. doi: 10.3748/wjg.v13.i6.950
Table 3 Methylation of SFRP2, HPP1 and MGMT in stool samples n (%)
| Diagnosis | No | Gene locus | Total | ||
| SFRP2 | HPP1 | MGMT | |||
| Cancer | 52 | 49 (94.2) | 37 (71.2) | 25 (48.1) | 50 (96.2) |
| Adenomas | 21 | 11 (52.4) | 12 (57.1) | 6 (28.6) | 15 (71.4) |
| Advanced adenomas | 10 | 7 (70.0) | 7 (70.0) | 4 (40.0) | 8 (80.0) |
| Hyperplastic polyp | 8 | 3 (37.5) | 2 (25.0) | 1 (12.5) | 3 (37.5) |
| Ulcerative colitis | 6 | 1 (16.7) | 1 (16.7) | 0 (0) | 1 (16.7) |
| Normal | 24 | 1 (4.2) | 0 (0) | 0 (0) | 1 (4.2) |
- Citation: Huang ZH, Li LH, Yang F, Wang JF. Detection of aberrant methylation in fecal DNA as a molecular screening tool for colorectal cancer and precancerous lesions. World J Gastroenterol 2007; 13(6): 950-954
- URL: https://www.wjgnet.com/1007-9327/full/v13/i6/950.htm
- DOI: https://dx.doi.org/10.3748/wjg.v13.i6.950